Trade

with

Amicus Therapeutics Inc
(NASDAQ: FOLD)
AdChoices
5.77
-0.17
-2.86%
After Hours :
-
-
-

Open

6.04

Previous Close

5.94

Volume (Avg)

241.08k (2.39M)

Day's Range

5.75-6.04

52Wk Range

1.77-7.63

Market Cap.

467.48M

Dividend Rate ( Yield )

-

Beta

1.76

Shares Outstanding

78.70M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 363.00k

    • Net Income

    • -59.63M

    • Market Cap.

    • 467.48M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -4,434.54

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.76

    • Forward P/E

    • -

    • Price/Sales

    • 270.27

    • Price/Book Value

    • 12.87

    • Price/Cash flow

    • -7.78

      • EBITDA

      • -61.38M

      • Return on Capital %

      • -57.29

      • Return on Equity %

      • -151.27

      • Return on Assets %

      • -57.29

      • Book Value/Share

      • 0.46

      • Shares Outstanding

      • 78.70M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 6.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -1.36

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -52.47

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -4,705.95

            • 39.38

            • Net Profit Margin

            • -4,434.54

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -4,798.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -4,573.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.36

              • 0.76

              • Current Ratio

              • 7.11

              • 2.92

              • Quick Ratio

              • 7.02

              • 2.35

              • Interest Coverage

              • -79.55

              • 38.02

              • Leverage Ratio

              • 3.25

              • 2.21

              • Book Value/Share

              • 0.46

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.92

                • 238.10

                • P/E Ratio 5-Year High

                • -8.40

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.83

                • 124.82

                • Price/Sales Ratio

                • 263.16

                • 8.94

                • Price/Book Value

                • 12.39

                • 8.12

                • Price/Cash Flow Ratio

                • -7.78

                • 47.85

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -151.27

                        (-77.20)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -57.29

                        (-43.00)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -124.84

                        (-73.30)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.01

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -64.18M
                      Operating Margin
                      -17,680.72
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -7.78
                      Ownership

                      Institutional Ownership

                      77.66%

                      Top 10 Institutions

                      74.18%

                      Mutual Fund Ownership

                      8.90%

                      Float

                      52.72%

                      5% / Insider Ownership

                      2.84%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • UBS (Lux) EF Biotech (USD)

                      •  

                        1,372,700

                      • -44.09

                      • 1.88

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,121,366

                      • 39.02

                      • 1.42

                      • Vanguard Extended Market Index Fund

                      •  

                        580,796

                      • 0.00

                      • 0.74

                      • Fidelity® Magellan® Fund

                      •  

                        562,204

                      • 0.00

                      • 0.71

                      • Putnam Global Health Care Fund

                      •  

                        407,042

                      • 0.00

                      • 0.56

                      • TFS Market Neutral Fund

                      •  

                        359,032

                      • 66.18

                      • 0.46

                      • Candriam Eqs L Biotechnology

                      •  

                        305,000

                      • -35.79

                      • 0.39

                      • Russell US Small Cap Equity Fund

                      •  

                        130,798

                      • -13.54

                      • 0.17

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Perceptive Advisors LLC

                      •  

                        12,339,444

                      • +1,176.98%

                      • 16.93

                      • GlaxoSmithKline PLC

                      •  

                        11,315,825

                      • +64.80%

                      • 17.59

                      • Redmile Group, LLC

                      •  

                        7,650,268

                      • -9.96%

                      • 10.50

                      • NEA Management Company, LLC

                      •  

                        5,653,029

                      • 0.00%

                      • 7.76

                      • Palo Alto Investors, LLC

                      •  

                        1,956,376

                      • -69.35%

                      • 2.49

                      • UBS Global Asset Management Zurich

                      •  

                        1,372,700

                      • -44.09%

                      • 1.88

                      • Vanguard Group, Inc.

                      •  

                        1,361,170

                      • +10.51%

                      • 1.87

                      • Sound Energy Partners, Inc.

                      •  

                        663,716

                      • +11.51%

                      • 0.91

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for...more a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone-Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a mon...moreotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within our core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.lessless

                      Key People

                      John F. Crowley

                      CEO/Chairman of the Board/Director

                      Mr. William (Chip) D. Baird, III

                      CFO/Secretary

                      John R. Kirk

                      Vice President, Divisional

                      Ms. Daphne E. Quimi

                      Chief Accounting Officer/Controller/Vice President, Divisional

                      Enrique Dilone

                      Vice President, Divisional

                      • Amicus Therapeutics Inc

                      • 1 Cedar Brook Drive

                      • Cranbury, NJ 08512

                      • USA.Map

                      • Phone: +1 609 662-2000

                      • Fax: +1 609 662-2001

                      • amicusrx.com

                      Incorporated

                      2002

                      Employees

                      92

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: